Selak V, Farquhar C, Prentice A, Singla A
Department of Obstetrics and Gynaecology, National Women's Hospital, Claude Road, Epsom, Auckland, New Zealand, 1003.
Cochrane Database Syst Rev. 2000(2):CD000068. doi: 10.1002/14651858.CD000068.
Endometriosis is defined as the presence of endometrial tissue (stromal and glandular) outside the normal uterine cavity. Conventional medical and surgical treatments for endometriosis aim to remove or decrease deposits of ectopic endometrium. The observation that hyperandrogenic states (an excess of male hormone) induce atrophy of the endometrium has led to the use of androgens in the treatment of endometriosis. Danazol is one of these treatments used. The efficacy of danazol is based on its ability to produce a high androgen/low estrogen environment (a pseudo menopause) which results in the atrophy of endometriotic implants and thus an improvement in painful symptoms.
To determine the effectiveness of danazol compared to placebo or no treatment in the treatment of the symptoms and signs, other than infertility, of endometriosis in women of reproductive age.
The Menstrual Disorders Group search strategy was used to identify randomised controlled trials of the use of danazol in endometriosis. In addition, all reference lists of included trials were searched, and relevant drug companies were contacted for details of unpublished trials
Randomised controlled trials in which danazol (alone or as adjunctive therapy) was compared to placebo or no therapy. Trials which only reported infertility outcomes were excluded.
Only four trials met the inclusion criteria and two authors extracted data independently from these trials. All four trials compared danazol to placebo. Two trials used danazol as sole therapy and two trials used danazol as an adjunct to surgery. Although the main outcome was pain improvement other data relating to laparoscopic scores and hormonal parameters were also collected.
Treatment with danazol (including adjunctive surgical therapy) was effective in relieving painful symptoms related to endometriosis when compared to placebo. Laparoscopic scores were improved with danazol treatment (including adjunctive therapy) when compared with either placebo or no treatment. Side effects were more commonly reported in those patients receiving danazol than placebo.
REVIEWER'S CONCLUSIONS: Danazol is effective in treating the symptoms and signs of endometriosis. However, its use is limited by the occurrence of androgenic side effects.
子宫内膜异位症的定义为正常子宫腔外存在子宫内膜组织(间质和腺体)。子宫内膜异位症的传统药物和手术治疗旨在清除或减少异位子宫内膜的沉积。高雄激素状态(雄性激素过多)会导致子宫内膜萎缩,这一观察结果促使人们使用雄激素来治疗子宫内膜异位症。达那唑就是其中一种治疗药物。达那唑的疗效基于其产生高雄激素/低雌激素环境(假绝经)的能力,这种环境会导致子宫内膜异位植入物萎缩,从而改善疼痛症状。
确定在治疗育龄期女性子宫内膜异位症(不包括不孕症)的症状和体征方面,达那唑与安慰剂或不治疗相比的有效性。
采用月经紊乱组的检索策略来识别使用达那唑治疗子宫内膜异位症的随机对照试验。此外,还检索了纳入试验的所有参考文献列表,并联系了相关制药公司以获取未发表试验的详细信息。
将达那唑(单独使用或作为辅助治疗)与安慰剂或不治疗进行比较的随机对照试验。仅报告不孕症结局的试验被排除。
只有四项试验符合纳入标准,两位作者独立从这些试验中提取数据。所有四项试验均将达那唑与安慰剂进行比较。两项试验将达那唑作为单一疗法,两项试验将达那唑作为手术辅助治疗。虽然主要结局是疼痛改善,但也收集了与腹腔镜评分和激素参数相关的其他数据。
与安慰剂相比,使用达那唑治疗(包括辅助手术治疗)在缓解与子宫内膜异位症相关的疼痛症状方面是有效的。与安慰剂或不治疗相比,达那唑治疗(包括辅助治疗)可改善腹腔镜评分。接受达那唑治疗的患者比接受安慰剂治疗的患者更常报告有副作用。
达那唑在治疗子宫内膜异位症的症状和体征方面是有效的。然而,其使用受到雄激素副作用发生的限制。